Event / Presentation

JUNE 7-10 | CHITOSE to give a Poster Presentation on CHO-MK at ESACT 2026

2026.05.22

CHITOSE will participate in the 29th Meeting of the European Society for Animal Cell Technology (ESACT), scheduled from June 7th to 10th, 2026, in Salzburg, Austria.

As ESACT celebrates its landmark 50th anniversary, CHITOSE will be joining global leaders in cell technology to discuss the future of biopharmaceutical manufacturing. We are excited to contribute to this milestone event through both our participation and a technical poster presentation showcasing our latest R&D technologies.

Poster Presentation 

  • Title: Developing an Intensified Fed-Batch Process of High-Productivity Novel CHO-MK for Optimal Therapeutic Protein Manufacturing
  • Time: Tuesday, June 9th, 2026 | 12:30 – 15:30
  • Presenter: Kevin Montagne (Senior BioEngineer, Tech & Biz Development Div.)

Visit to discover how CHITOSE’s proprietary CHO-MK host cell line can be leveraged to accelerate your manufacturing timeline. We look forward to meeting you onsite.

Contact: biologics.contactchitose-bio.com
*replace with @

Event Overview
Event Name: 29th ESACT Meeting
Date and Time: Sunday, June 7th – Wednesday, June 10th, 2026
Venue: Messezentrum Salzburg, Austria

About CHITOSE’s Cell Line Development Service
https://biologics.chitose-bio.com/
Through over 10 years of research, CHITOSE has developed the highly productive CHO-MK host cell line and designed the original Chitose Super CHO expression system (CS CHO). With the combination of these innovations, we have established an extremely robust and flexible system to address the needs for a faster and more cost-effective cell line-based protein expression platform.

Related Information
[Press Release] The University of Tokyo and Chitose Laboratory Drive New Development in Digital Design for Manufacturing Process of Antibody Drugs
[Press Release] CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing
[News] Paper on Novel CHO-MK Cell Line Receives 2025 Excellent Paper Award from the Society of Biotechnology, Japan
[Press Release] High-Performance Novel HAT Cell Line for Gene Therapy, Published in Molecular Therapy Methods & Clinical Development, and Ready for Commercial Use

Prev

view all news

Next